Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer. - Wikidata - awgldk - TriplyDB

Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer.

Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer.

http://www.wikidata.org/entity/Q35618817

about

miRNA Influences in NRF2 Pathway Interactions within Cancer Models ZEB1: at the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance The emerging molecular machinery and therapeutic targets of metastasis MicroRNA in radiotherapy: miRage or miRador?The microRNA-200 family: small molecules with novel roles in cancer development, progression and therapy In Vivo Delivery of miR-34a Sensitizes Lung Tumors to Radiation Through RAD51 Regulation Therapeutic use of microRNAs in lung cancer MicroRNAs Used in Combination with Anti-Cancer Treatments Can Enhance Therapy Efficacy miR-8 modulates cytoskeletal regulators to influence cell survival and epithelial organization in Drosophila wings.MicroRNA-124 regulates the radiosensitivity of non-small cell lung cancer cells by targeting TXNRD1 microRNA-200c/141 upregulates SerpinB2 to promote breast cancer cell metastasis and reduce patient survival.miR-200c-driven Mesenchymal-To-Epithelial Transition is a Therapeutic Target in Uterine Carcinosarcomas.The Functions of MicroRNA-200 Family in Ovarian Cancer: Beyond Epithelial-Mesenchymal Transition.Integrated Molecular Characterization of Uterine Carcinosarcoma.Development of small RNA delivery systems for lung cancer therapy.MicroRNA as tools and therapeutics in lung cancer Epstein-Barr Virus MicroRNA Expression Increases Aggressiveness of Solid Malignancies.Monitoring integrity and localization of modified single-stranded RNA oligonucleotides using ultrasensitive fluorescence methods.Tracking miRNAs' footprints in tumor-microenvironment interactions: Insights and implications for targeted cancer therapy.PDL1 Regulation by p53 via miR-34 Predicting MicroRNA Biomarkers for Cancer Using Phylogenetic Tree and Microarray Analysis.Interplay between Reactive oxygen Species and MicroRNAs in Cancer.Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: Νew trends in the development of miRNA therapeutic strategies in oncology (Review).Up- regulation of miR-328-3p sensitizes non-small cell lung cancer to radiotherapy.Plasma miRNAs in predicting radiosensitivity in non-small cell lung cancer.MiRNA expression profiles in the brains of mice infected with scrapie agents 139A, ME7 and S15.MiRNA-based therapeutic intervention of cancer.A novel fine tuning scheme of miR-200c in modulating lung cell redox homeostasis.Missing link between microRNA and prostate cancer.MicroRNAs in non-small cell lung cancer invasion and metastasis: from the perspective of the radiation oncologist.miRNA nanotherapeutics for cancer.MicroRNA-targeted therapeutics for lung cancer treatment.miRNAs: micro-managers of anticancer combination therapies.Overexpression of miR-100 inhibits cancer growth, migration, and chemosensitivity in human NSCLC cells through fibroblast growth factor receptor 3.Translational Significance for Tumor Metastasis of Tumor-Associated Macrophages and Epithelial-Mesenchymal Transition The Role and Mechanism of Epithelial-to-Mesenchymal Transition in Prostate Cancer Progression.Potential role of ZEB1 as a DNA repair regulator in colorectal cancer cells revealed by cancer-associated promoter profiling.Disruption of the c-Myc/miR-200b-3p/PRDX2 regulatory loop enhances tumor metastasis and chemotherapeutic resistance in colorectal cancer.Some chemotherapeutics-treated colon cancer cells display a specific phenotype being a combination of stem-like and senescent cell features.Using Genome Sequence to Enable the Design of Medicines and Chemical Probes.

P2860

Q26783311-E7C5E645-806B-47B2-8BD0-42F769605407 Q27015111-5AC7228B-D1EC-48A4-A188-6A78EE137C2D Q27022207-2FE42FBB-E43E-493B-A3A9-220C8F28934E Q27025405-31795ED5-0F0E-4C22-959C-2B6E8B24EB50 Q28083742-74BFA60C-DBCE-49F0-A852-38291E44F198 Q28271063-05907EC7-7F47-47C1-ABD8-F756EDBE1AA0 Q28395179-F8D19DE8-2BFF-48B9-97D4-1FD69580E889 Q28829013-835A22C0-64A4-444D-B314-E9D0B49DD457 Q30359720-66B99C10-2A67-4679-B078-ECC2F0597E25 Q33598177-D75F8C0E-2510-467A-B23E-3960463519B1 Q33779244-E25D2DC9-C088-43DA-B9A5-F72B8C834E42 Q33804175-632C1D61-B4E1-4B46-9E2C-7BD9AF63FFF8 Q33838714-89688E09-C45C-408D-A827-9E2109A411E4 Q34681051-3012C18F-B771-425E-9914-344D106EB7F1 Q35380932-3D6F53CA-F1E7-41FE-97B4-C53F8283A94D Q35738706-C7E01025-140C-493F-90CC-2EF0945E6BE1 Q35777091-B13EDE79-3760-4CB4-8570-F76B172E400F Q36302402-ACD0C087-1658-4EA2-A702-2AC58D7B15AF Q36319389-507EDBE5-8BC2-496A-9516-310A1231FA64 Q36887608-7E8128EB-4FB3-4592-A62B-A6181E27E298 Q36939358-1FC3D8FA-FBFD-4B50-87E4-86154FFB3F68 Q36973327-F1F65CBD-5C46-4A4C-9F47-FBDED2E30448 Q36992190-BA4EB958-EA9D-4027-A2CD-A9AF2ECA9DA9 Q37181618-7443F205-A653-4FD1-9CE6-D981EAB670CC Q37366231-8EAD870F-4062-4EDE-8665-77D009CC6BF5 Q37489927-72E6D1CF-5E5C-4B99-84B4-BB5394821173 Q38524274-E2AA53C0-1004-4753-8AE6-B74F3DF94BF2 Q38698165-E5B2B6D0-2E6F-446F-96A4-8CF3BFD760E3 Q38715316-B20758F8-3BDB-4E80-B84A-FFED60360AFA Q38841996-CD4F1260-A3A2-4208-9A06-5D7C5403172A Q38999082-5B06C39C-9604-40D4-8924-11A75B9BE32D Q39014580-3F734ED9-E2B1-4508-96E0-05AED4B11986 Q39285150-50CEE1E3-2E9D-4E30-9871-F9AE3C6873BA Q40599368-795A3030-23D2-4F21-BECB-4AE051BEAD25 Q41684073-3F083895-479D-4CBE-B3E7-809DABC9196D Q47112301-C8C0A8EA-44CF-4D65-B9D5-411574D2E2FB Q47118073-D8DDB876-9EBC-44BD-B448-5AAE8FBC41BD Q47162615-0A4BAA92-2941-4CB9-9E4A-258E91363642 Q47624450-60DD124E-F778-4144-BF92-A67A694759B7 Q48263612-254D4BDA-ABC7-4616-868E-904B2C1747F6

P2860

Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer.

http://www.wikidata.org/entity/Q35618817

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer.

@ast

Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer.

@en

type

label

Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer.

@ast

Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer.

@en

prefLabel

Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer.

@ast

Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer.

@en

P1433

Q35618817-42A67F21-0D97-4CB5-9C6D-54B3D5860642

P1476

Q35618817-0CBCE0A3-0D7C-42F0-B727-A512A9D4D112

P2093

Q35618817-0F822D6C-FDE9-4DF5-994C-582EE1229EAD

Q35618817-0FC3029F-B4FE-49E5-A98C-CAA8865AF34E

Q35618817-2B69DD4A-C3C3-443F-ABC7-0598B0A9589E

Q35618817-38D47C32-D720-4512-8448-E2223965958C

Q35618817-4ED3E0F0-6B0B-4D4B-A81D-4E7D08C91CD3

Q35618817-7C3D4D81-6A85-45DF-92A5-B0746F5A860F

Q35618817-88036EFA-F649-4C92-8016-958AB4DE3D34

Q35618817-A44A2368-E716-4651-98D6-06C3983053D4

Q35618817-C6DA1146-609C-4B9C-B4A9-3CCDD65EDC6A

Q35618817-CB6BB0BA-3175-4334-A00D-7AE08143EF95

P2860

Q35618817-156B9A1E-0DC3-429A-A99C-03C9BE57BB5F

Q35618817-1FDCCBAE-8B73-4B62-8206-726B07A250B1

Q35618817-3B732461-5804-4F92-A5A1-17AFDE528267

Q35618817-3DED2670-1399-4769-BE73-A83EECF6A7DE

Q35618817-42BF4C2C-6662-4E0B-A9D6-5184DA39F09D

Q35618817-5175C771-BBB9-4D11-8187-5766E963D006

Q35618817-541C600C-E95D-4354-A579-981ED1D75BAB

Q35618817-547417ED-888F-4D3E-B30B-D87F9902AF75

Q35618817-5EF67F68-0BE7-47C6-BDB8-8DC56F6D4BC3

Q35618817-600A86B2-4D29-4023-AA0B-180B26A9D873

P304

Q35618817-35E5D12B-C469-4B17-B9E8-133A29D2BFF1

P31

Q35618817-74FCF2C9-A267-4DFA-BEB5-BD77D3A3CCA0

P356

Q35618817-3D057C30-A2F4-4543-8A24-BC41BE1DC07B

P433

Q35618817-522A6262-17F0-4208-B16F-949941252862

P478

Q35618817-935628B2-40AF-4F06-BAC6-5A1FFB17C47B

P50

Q35618817-739AF80B-71EE-41C9-ABE3-8AB94C3BD895

Q35618817-F659F92A-42DA-4C88-8565-CCC75E6ADA44

Q35618817-FEC6AA71-7DBC-48FC-9576-E712A97ACE4D

P577

Q35618817-84B6ABEA-7F59-4D11-A743-0D73BB54E46D

P5875

Q35618817-EE0470E7-3648-4DF6-AF76-02D922C82CB6

P698

Q35618817-D95E04DB-4C2D-4AE3-A6EF-F008007270D2

P932

Q35618817-C3EDA24B-D8FF-4480-A8B2-29BFCC607121

P356

P1433

Molecular Therapy

P1476

Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer.

@en

P2093

Andreas G Bader

http://www.w3.org/2001/XMLSchema#string

Caio C Quini

http://www.w3.org/2001/XMLSchema#string

David Valdecanas

http://www.w3.org/2001/XMLSchema#string

Dipak K Giri

http://www.w3.org/2001/XMLSchema#string

Heidi J Peltier

http://www.w3.org/2001/XMLSchema#string

James W Welsh

http://www.w3.org/2001/XMLSchema#string

Maria Angelica Cortez

http://www.w3.org/2001/XMLSchema#string

Raymond E Meyn

http://www.w3.org/2001/XMLSchema#string

Tatiana Wolfe

http://www.w3.org/2001/XMLSchema#string

Vikas Bhardwaj

http://www.w3.org/2001/XMLSchema#string

P2860

The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2

The ZEB/miR-200 feedback loop--a motor of cellular plasticity in development and cancer?

Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes

The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2

A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells

Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model

Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets

MicroRNA signatures in human cancers

The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1

ATP-dependent reduction of cysteine-sulphinic acid by S. cerevisiae sulphiredoxin.

P304

1494-1503

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2014.79

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

George A. Calin

P577

2014-05-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262050388

http://www.w3.org/2001/XMLSchema#string

P698

24791940

http://www.w3.org/2001/XMLSchema#string

P932

4435581

http://www.w3.org/2001/XMLSchema#string